Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pfizer (NY: PFE ) 29.85 +0.10 (+0.34%) Streaming Delayed Price Updated: 11:00 AM EDT, Sep 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Pfizer < Previous 1 2 3 4 5 6 7 8 9 ... 99 100 Next > Current Report: Pfizer (PFE) Today 3:25 EDT Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer's share price fell about 12.7% from $34.07 to $29.75 as of Wednesday’s... Via Talk Markets 10 Health Care Stocks With Whale Alerts In Today's Session September 18, 2024 Via Benzinga Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse September 18, 2024 Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and... Via Benzinga 3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever September 18, 2024 After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement. Via The Motley Fool Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030 September 18, 2024 These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. Via The Motley Fool Pfizer Unusual Options Activity September 17, 2024 Via Benzinga Beyond The Numbers: 13 Analysts Discuss Pfizer Stock September 16, 2024 Via Benzinga Is Pfizer's 5.7% Dividend Yield Worth the Risk? September 15, 2024 Pfizer's sky-high dividend yield is tempting, but is it sustainable? Via The Motley Fool Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts September 17, 2024 From Pfizer Inc. Via Business Wire 1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) September 17, 2024 Telemedicine once seemed like it was going to revolutionize healthcare. Via The Motley Fool Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns September 17, 2024 The September syndrome is already visible in U.S. stock markets. At this stage, investment in stocks with high dividend yield strong price appreciation potential in the short term should enhance... Via Talk Markets Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today September 16, 2024 On Monday, major U.S. indices showed mixed results. The Dow Jones Industrial Average closed 0.5% higher at 41,622.08 Via Benzinga Topics Stocks Exposures US Equities Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So. September 16, 2024 The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling. Via The Motley Fool Topics Supply Chain Exposures Supply Chain DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions September 16, 2024 Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... Via Benzinga Exposures COVID-19 Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer September 16, 2024 Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr.... Via Newsfile Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia September 14, 2024 From Pfizer Inc. Via Business Wire Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer September 14, 2024 From Pfizer Inc. Via Business Wire Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day September 13, 2024 The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday. Via Investor's Business Daily Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now September 13, 2024 These stocks all trade at less than 14 times their expected future profits. Via The Motley Fool Should You Buy Novavax Stock After This Regulatory Win? September 13, 2024 The biotech continues to earn important wins, but is it enough? Via The Motley Fool A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now September 13, 2024 These players have had their ups and downs -- but the future looks bright. Via The Motley Fool Alnylam Stock Soars 65%: Find Out What’s Behind the Gains September 12, 2024 Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug. Via MarketBeat Exposures Product Safety UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars September 11, 2024 UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. Via Benzinga GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech September 11, 2024 GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV... Via Benzinga Is Hims & Hers Health the Next Teladoc? September 11, 2024 Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. Via The Motley Fool Exposures COVID-19 Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 September 11, 2024 From Pfizer Inc. Via Business Wire 2 Beaten-Down Stocks That Could Be Great Buys on the Dip September 11, 2024 They're down but not out, at least not yet. Via The Motley Fool 3 High-Yield Stocks to Buy Hand Over Fist in September September 10, 2024 The time is right to buy all three of these high-yield dividend stocks. Via The Motley Fool Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 99 100 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.